Choose Bpc-157 When Facing Tendon injuries including tennis elbow, golfers elbow, Achilles tendonitis, patellar tendinopathy, and rotator cuff issues Ligament damage especially partial tears and sprains Gastrointestinal problems including ulcers, IBD, IBS, gastritis, and leaky gut Need to protect tissues from corticosteroid damage Nerve tissue protection and neuroprotection applications Single localized injury requiring targeted repair Bpc-157 uniquely prevents corticosteroid damage to tendons, directly upregulates growth hormone receptors on tendon fibroblasts, and can be taken orally with maintained bioavailability for gut issues

TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
This includes bunion correction and selected other foot and ankle procedures
The mast cells mainly reside in connective tissue, in which the extracellular matrix is made of proteins that hold the tissue together
By combining high-purity peptides with precise, careful technique, you set the stage for generating meaningful, impactful data
PMCID: PMC9273750